Abstract

REMDESIVIER; CLINICAL SIGNIFICANCE, IMPLICATIONS, CHEMISTRY AND, MEDICINAL SYNTHESIS

Saurabh Dilip Bhandare*

.

Abstract

An outbreak of novel corona-virus (2019-nCoV) that began in Wuhan, China, had spread rapidly, with cases now confirmed in multiple countries. Early data reveal the results outcome that Remdesivir is effective against COVID-19. Social media platforms are inundated with requests for Remdesivir, a critical drug in the treatment of COVID-19 that is in short supply throughout the country, (India). Remdesivier is a broad-sprectrum antiviarl drug used as a medication for the treatment of COVID-19. Remdesivir was approved for medical use in the United States in October 2020. The U.S. Food and Drug Administration (FDA) approved Remdesivir based on the agency's analysis of data from three randomised, controlled clinical trials that included participants hospitalised with mild-to-severe COVID-19. The FDA granted approval and reissued the revised EUA to Gilead Sciences Inc. The FDA approved Remdesivir based primarily on evidence from three clinical trials (NCT04280705, NCT04292899, and NCT04292730) of 2043 hospitalised participants with COVID-19. The trials were conducted at 226 sites in 17 countries including the United States of America. The results and outcomes are been discussed with the significant study for the use of Remdesivier as a therapeutic agent in the curing and mitigation of the disease or infection caused by the SARS-CoV-2 and other similar type of viral affecting the human as well as animal species.

Keywords: COVID-19 pandemic medication, Remdesivier synthesis scheme, Pharmacokinetics of Remdesivier, SARS-Cov-2 treatment Remdesivier, Faith and pharmacology of Remdesivier.